Commentary on Delayed Diagnosis of a Rare Metabolic Disorder in Adulthood
The Journal of Applied Laboratory Medicine · 01.07.2026 · 11 (4) · 959-960
DOI: 10.1093/jalm/jfag032 ↗Kurz gefasst
Editorial in der Zeitschrift The Journal of Applied Laboratory Medicine, online erschienen am 24.03.2026. Verfasst von Sharon Markham Geaghan. Beteiligte Einrichtung: Department of Pathology, Stanford University School of Medicine, Stanford, CA, United States. Die Arbeit nennt 2 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Mensah and colleagues present an elderly man with massive splenomegaly, skeletal abnormalities, electrocardiograph and laboratory evidence of cardiac dysfunction, unexplained anemia and thrombocytopenia. The diagnostic odyssey led to a late-in-life diagnosis of Gaucher disease (GD), an autosomal recessive lysosomal storage disorder caused by mutations in the GBA1 gene, which controls glucocerebrosidase enzyme production. The rarity and nonspecific symptoms of GD contribute to frequently delayed or entirely missed diagnoses. Earlier diagnosis is advantageous given available enzyme replacement and substrate reduction therapies, and adjunctive therapies to reduce bone loss and pain. A consensus recommendation offers a simple, achievable goal: GD should be included in the differential diagnosis for patients with unexplained thrombocytopenia or anemia and splenomegaly (1). Adoption of this practice recommendation could potentially change the health and well-being of many lives. Diagnostic algorithms for GD have evolved with scientific advancement. Bone marrow biopsy is invasive, painful, and not now required (1). A recent consensus recommendation is to use the biomarker lysosomal acid-β-glucosidase (Lyso-Gb1) as the first-line diagnostic test for GD. Panelists unanimously agreed that whole GBA1 sequence testing should always be performed to confirm diagnoses based on Lyso-Gb1 (1). Use of targeted panels for the most common GD mutations will miss many of the >400 pathogenic variants. However, GBA1 sequencing and interpretation is complex: a 96% homologous pseudogene, GBA1LP, only 16 kb away on chromosome 1, leads to a high rate of recombination events and chimeric alleles that can be missed by short-read sequencing. GBA1 long-read single-molecule real-time sequencing yields essential information that cannot be obtained by short-read Sanger or next-generation sequencing alone (2). It has long been noted, but not understood, that the disease course varies even amongst siblings. There is increasing recognition that GBA1 sequencing, using specialized techniques, holds the key for better understanding and genotype–phenotype prognostication for this disease. Nonstandard Abbreviations: GD, Gaucher disease; Lyso-Gb1, lysosomal acid-β-glucosidase. Human Genes: GBA1, glucosylceramidase beta 1; GBA1LP, glucosylceramidase beta 1 like, pseudogene. Author Contributions: The corresponding author takes full responsibility that all authors on this publication have met the following required criteria of eligibility for authorship: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved. Nobody who qualifies for authorship has been omitted from the list. Authors’ Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Research Funding: None declared. Disclosures: S.M. Geaghan has received support from the United States FDA as a Special Government Employee, Medical Devices Division; received an honorarium for Outstanding Contributions to Pediatric Maternal Fetal Laboratory Medicine Prize; travel support from ADLM, IFCC, and CLSI for meeting attendance; honorarium from the American Society of Clinical Pathologists; consultant fees from BD and Canaan Ventures; and has had roles as an associate editor (The Journal of Applied Laboratory Medicine, ADLM; through 2025); IFCC, Chair, (ET-PLM) Microsampling Work Group; IFCC, Emerging Technologies in Pediatric Maternal Fetal Laboratory Medicine, Consultant; and UK-based Patient Centered Sampling Interest Group (PCSIG), speaker (unpaid).
Autor:innen und Institutionen
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, United States.
Zitieren
APA
Geaghan, S. M. (2026). Commentary on Delayed Diagnosis of a Rare Metabolic Disorder in Adulthood. The Journal of Applied Laboratory Medicine, 11(4), 959-960. https://doi.org/10.1093/jalm/jfag032
Vancouver
Geaghan SM. Commentary on Delayed Diagnosis of a Rare Metabolic Disorder in Adulthood. The Journal of Applied Laboratory Medicine. 2026;11(4):959-960. doi:10.1093/jalm/jfag032
BibTeX
@article{Geaghan2026,
author = {Geaghan, Sharon Markham},
title = {Commentary on Delayed Diagnosis of a Rare Metabolic Disorder in Adulthood},
journal = {The Journal of Applied Laboratory Medicine},
year = {2026},
volume = {11},
number = {4},
pages = {959--960},
doi = {10.1093/jalm/jfag032}
}
EUVIMED